{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-030407","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.489060+00:00","generated_at":"2026-05-25T18:44:34.331017+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PMV Pharma reports FY2024 net loss of $58.7M; cash runway to end of 2026; Phase 2 interim data mid-2025","bullets":["Net loss of $58.7M for FY2024, compared to $69.0M in FY2023; no revenue.","Cash, cash equivalents & marketable securities of $183.3M as of Dec 31, 2024; provides cash runway to end of 2026.","Phase 2 PYNNACLE trial enrollment on track; interim analysis data expected mid-2025; NDA submission anticipated by end of 2026.","Discontinued enrollment in Phase 1b combination arm of rezatapopt with pembrolizumab due to lack of clinically meaningful benefit.","Enrollment commenced in investigator-initiated Phase 1b study of rezatapopt in relapsed/refractory AML/MDS with TP53 Y220C mutation."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-030407","json":"https://secwatch.observer/filing/0000950170-25-030407.json","markdown":"https://secwatch.observer/filing/0000950170-25-030407.md","text":"https://secwatch.observer/filing/0000950170-25-030407.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000095017025030407/0000950170-25-030407-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000095017025030407/pmvp-20250303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T18:44:34.331017+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}